Comparative Burden of Metabolic Dysfunction in Lean NAFLD vs Non-lean NAFLD - A Systematic Review and Meta-analysis
- PMID: 35863685
- DOI: 10.1016/j.cgh.2022.06.029
Comparative Burden of Metabolic Dysfunction in Lean NAFLD vs Non-lean NAFLD - A Systematic Review and Meta-analysis
Abstract
Background & aims: Nonalcoholic fatty liver disease (NAFLD) is traditionally associated with obesity. However, there is a subtype of NAFLD, namely NAFLD in lean, that occurs without obesity. However, a recent call to redefine NAFLD to metabolic-associated fatty liver disease focuses on obesity and metabolic dysfunction. Criticism has arisen from the perceived over emphasis on systemic comorbidities, which may disadvantage the lean. The current analysis seeks to quantify the degree of metabolic dysfunction in NAFLD in lean and compare with NAFLD in overweight and obese and non-NAFLD.
Methods: Medline and Embase databases were searched from inception to March 3, 2022. The inclusion criteria were articles with NAFLD in lean patients presenting with baseline metabolic parameters. Comparisons were conducted with subgroup analysis.
Results: Eighty-five articles were included in the meta-analysis. NAFLD in lean accounted for 13.11% (95% confidence interval [CI], 10.26%-16.62%) of the global population and 14.55% (95% CI, 11.32%-18.51%) in Asia. The degree of metabolic dysfunction was weight dependent with significantly less metabolic dysfunction in NAFLD in lean subjects as compared with NAFLD in overweight counterparts. For NAFLD in lean, only 19.56% (95% CI, 15.28%-24.69%) of the subjects were diabetic, whereas 45.70% (95% CI, 35.01%-56.80%) of obese subjects with NAFLD had diabetes (P < .01). Fasting blood glucose and systolic and diastolic blood pressure values were significantly lower in subjects with NAFLD in lean than in overweight and obese.
Conclusion: The current analysis highlights the weight-dependent nature of metabolic dysfunction in NAFLD. Lean subjects with NAFLD were significantly less metabolically unhealthy than were obese and overweight persons with NAFLD. An overreliance on metabolic dysfunction in defining fatty liver will be a flaw in potentially excluding previously characterized NAFLD.
Keywords: MAFLD; Metabolic Associated Fatty Liver Disease Definition; NAFLD; NAFLD in obese.
Copyright © 2023 AGA Institute. All rights reserved.
Similar articles
-
Systematic review with meta-analysis: the significance of histological disease severity in lean patients with nonalcoholic fatty liver disease.Aliment Pharmacol Ther. 2018 Jan;47(1):16-25. doi: 10.1111/apt.14401. Epub 2017 Oct 30. Aliment Pharmacol Ther. 2018. PMID: 29083036
-
Heterogeneity of cardiometabolic and hepatic fibrosis risks in nonalcoholic fatty liver disease among lean, overweight, and obese populations: a multicenter cross-sectional study.Eur J Gastroenterol Hepatol. 2025 Aug 1;37(8):975-981. doi: 10.1097/MEG.0000000000002977. Epub 2025 Jun 18. Eur J Gastroenterol Hepatol. 2025. PMID: 40359275
-
Systematic review with meta-analysis: risk factors for non-alcoholic fatty liver disease suggest a shared altered metabolic and cardiovascular profile between lean and obese patients.Aliment Pharmacol Ther. 2017 Jul;46(2):85-95. doi: 10.1111/apt.14112. Epub 2017 May 2. Aliment Pharmacol Ther. 2017. PMID: 28464369
-
Metformin for women who are overweight or obese during pregnancy for improving maternal and infant outcomes.Cochrane Database Syst Rev. 2018 Jul 24;7(7):CD010564. doi: 10.1002/14651858.CD010564.pub2. Cochrane Database Syst Rev. 2018. PMID: 30039871 Free PMC article.
-
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.Health Technol Assess. 2001;5(28):1-110. doi: 10.3310/hta5280. Health Technol Assess. 2001. PMID: 11701100
Cited by
-
Trends and predictions of metabolic risk factors for acute myocardial infarction: findings from a multiethnic nationwide cohort.Lancet Reg Health West Pac. 2023 May 31;37:100803. doi: 10.1016/j.lanwpc.2023.100803. eCollection 2023 Aug. Lancet Reg Health West Pac. 2023. PMID: 37693863 Free PMC article.
-
Clinical Classification of Obesity and Implications for Metabolic Dysfunction-Associated Fatty Liver Disease and Treatment.Diabetes Metab Syndr Obes. 2023 Oct 25;16:3303-3329. doi: 10.2147/DMSO.S431251. eCollection 2023. Diabetes Metab Syndr Obes. 2023. PMID: 37905232 Free PMC article. Review.
-
Diagnostic Utility of Triglyceride-Glucose Index in Non-Alcoholic Fatty Liver Disease: A Cross-Sectional Study on Lean Population.Diabetes Metab Syndr Obes. 2024 Sep 21;17:3547-3556. doi: 10.2147/DMSO.S469398. eCollection 2024. Diabetes Metab Syndr Obes. 2024. PMID: 39328264 Free PMC article.
-
Intestinal Microbiota Modulation by Fecal Microbiota Transplantation in Nonalcoholic Fatty Liver Disease.Biomedicines. 2025 Mar 23;13(4):779. doi: 10.3390/biomedicines13040779. Biomedicines. 2025. PMID: 40299326 Free PMC article. Review.
-
The Association between Personality Factors and Metabolic Parameters among Patients with Non-Alcoholic-Fatty Liver Disease and Type 2 Diabetes Mellitus-A Cross-Sectional Study.J Clin Med. 2023 Jul 3;12(13):4468. doi: 10.3390/jcm12134468. J Clin Med. 2023. PMID: 37445503 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous